Valeritas V-Go Insulin Delivery 2016 Canaccord Forum

Valeritas presented its V-Go disposable insulin delivery device at the 2016 Canaccord Genuity Medical Technology & Diagnostics Forum. The company highlighted approximately $20M in revenue with 35% gross margins, over 10 million V-Go units dispensed, and established reimbursement through commercial and Medicare Part D channels targeting 4.6M Type 2 diabetes patients on insulin.